Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes

Abstract

The patency of the ductus arteriosus is very common in extremely premature infants. The increased pulmonary blood flow that results from left-to-right ductal shunting can produce an acute deterioration in lung function and some data suggest that it may increase the risk of chronic lung damage. However, there is no clear evidence that prophylactic or early closure of the patent ductus arteriosus (PDA) results in a clear reduction in bronchopulmonary dysplasia. For this reason, and because of the side effects of the available therapies to close the ductus, there is a wide variation in the approach to the PDA in this population and most clinicians will intervene to close the ductus only in cases of significant shunt with hemodynamic decompensation.

Keywords

extreme low birth weight infant - bronchopulmonary dysplasia - lung development - pulmonary blood flow - patent ductus arteriosus

• References

• 1 Stefano JL, Abbasi S, Pearlman SA, Spear ML, Esterly KL, Bhutani VK. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation. Am Rev Respir Dis 1991; 143 (02) 236-239
• 2 Heldt GP, Pesonen E, Merritt TA, Elias W, Sahn DJ. Closure of the ductus arteriosus and mechanics of breathing in preterm infants after surfactant replacement therapy. Pediatr Res 1989; 25 (03) 305-310
• 3 Abman SH. Pulmonary hypertension in chronic lung disease of infancy: Pathogenesis, pathophysiology and treatment. In: Bland RD, Coalson JJ. eds. Chronic Lung Disease of Infancy. New York, NY: Taylor & Francis Inc; 1999
• 4 Herget J, Hampl V, Povýsilová V, Slavík Z. Long-term effects of prenatal indomethacin administration on the pulmonary circulation in rats. Eur Respir J 1995; 8 (02) 209-215
• 5 Broccard AF, Hotchkiss JR, Kuwayama N. , et al. Consequences of vascular flow on lung injury induced by mechanical ventilation. Am J Respir Crit Care Med 1998; 157 (6 Pt 1): 1935-1942
• 6 Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1988; 112 (01) 67-72
• 7 Abman SH, Wolfe RR, Accurso FJ, Koops BL, Bowman CM, Wiggins Jr JW. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics 1985; 75 (01) 80-84
• 8 McCurnin D, Seidner S, Chang LY. , et al. Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. Pediatrics 2008; 121 (05) 945-956
• 9 Chang LY, McCurnin D, Yoder B, Shaul PW, Clyman RI. Ductus arteriosus ligation and alveolar growth in preterm baboons with a patent ductus arteriosus. Pediatr Res 2008; 63 (03) 299-302
• 10 Gonzalez A, Sosenko IRS, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996; 128 (04) 470-478
• 11 Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126 (04) 605-610
• 12 Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonate 1980; 38 (1–2): 96-105
• 13 Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr 1996; 128 (5 Pt 1): 601-607
• 14 Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001; 138 (02) 205-211
• 15 Schmidt B, Davis P, Moddemann D. , et al; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344 (26) 1966-1972
• 16 Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010; 7 (07) CD000174
• 17 Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?. J Perinatol 2010; 30 (04) 241-252
• 18 Sosenko IR, Fajardo MF, Claure N, Bancalari E. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. J Pediatr 2012; 160 (06) 929-35.e1
• 19 Kluckow M, Jeffery M, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2014; 99 (02) F99-F104
• 20 Moin F, Kennedy KA, Moya FR. Risk factors predicting vasopressor use after patent ductus arteriosus ligation. Am J Perinatol 2003; 20 (06) 313-320
• 21 Madan JC, Kendrick D, Hagadorn JI, Frantz III ID. ; National Institute of Child Health and Human Development Neonatal Research Network. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009; 123 (02) 674-681